- Home
- SOFI vs NBIX Comparison
SOFI vs NBIX Comparison
Compare SOFI & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOFI
- NBIX
- Stock Information
- Founded
- SOFI 2011
- NBIX 1992
- Country
- SOFI United States
- NBIX United States
- Employees
- SOFI N/A
- NBIX N/A
- Industry
- SOFI Diversified Financial Services
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SOFI Finance
- NBIX Health Care
- Exchange
- SOFI Nasdaq
- NBIX Nasdaq
- Market Cap
- SOFI 16.1B
- NBIX 13.7B
- IPO Year
- SOFI N/A
- NBIX 1996
- Fundamental
- Price
- SOFI $17.90
- NBIX $145.88
- Analyst Decision
- SOFI Hold
- NBIX Buy
- Analyst Count
- SOFI 16
- NBIX 22
- Target Price
- SOFI $11.36
- NBIX $164.81
- AVG Volume (30 Days)
- SOFI 36.9M
- NBIX 926.1K
- Earning Date
- SOFI 01-27-2025
- NBIX 02-05-2025
- Dividend Yield
- SOFI N/A
- NBIX N/A
- EPS Growth
- SOFI N/A
- NBIX 97.40
- EPS
- SOFI 0.12
- NBIX 3.73
- Revenue
- SOFI $2,519,211,000.00
- NBIX $2,242,800,000.00
- Revenue This Year
- SOFI N/A
- NBIX $27.18
- Revenue Next Year
- SOFI $18.09
- NBIX $17.92
- P/E Ratio
- SOFI $151.08
- NBIX $39.13
- Revenue Growth
- SOFI 32.15
- NBIX 25.72
- 52 Week Low
- SOFI $6.01
- NBIX $110.95
- 52 Week High
- SOFI $18.10
- NBIX $157.98
- Technical
- Relative Strength Index (RSI)
- SOFI 67.66
- NBIX 70.01
- Support Level
- SOFI $13.60
- NBIX $138.66
- Resistance Level
- SOFI $15.62
- NBIX $144.24
- Average True Range (ATR)
- SOFI 0.70
- NBIX 3.32
- MACD
- SOFI 0.21
- NBIX 0.23
- Stochastic Oscillator
- SOFI 95.56
- NBIX 96.20
About SOFI SoFi Technologies Inc.
SoFi is a financial-services company that was founded in 2011 and is based in San Francisco. Initially known for its student loan refinancing business, the company has expanded its product offerings to include personal loans, credit cards, mortgages, investment accounts, banking services, and financial planning. The company intends to be a one-stop shop for its clients' finances and operates solely through its mobile app and website. Through its acquisition of Galileo in 2020, the company also offers payment and account services for debit cards and digital banking.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.